Alterations in the blood‐based biomarker testing performances following correction for renal function

Abstract

Background: Blood‐based biomarkers (BBMs), including plasma phosphorylated tau ( p ‐tau), have been expected as a promising, less‐invasive tool for detecting Alzheimer's disease (AD) pathology in real‐world applications.

The paper